Answers are grounded in this paper and cite their sources.
Acid secretion inhibitors are associated with hypergastrinemia, which can lead to gastric mucosal changes. Potassium-competitive acid blockers, such as vonoprazan, are more potent than proton pump inhibitors, but long-term safety data are lacking.
No takes yet. Share an insight, caveat, or question.
Uemura et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: